trial

A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation

NCTId NCT00723606
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 376 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2009-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
376 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2008-09
Primary completion
2009-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ZiprasidoneHaloperidol

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

9 total
Baoding, ChinaWuhan, ChinaKunming, ChinaBeijing, ChinaBeijing, ChinaChangsha, ChinaGuangzhou, ChinaNanjing, ChinaXi'an, China

Linked catalysts

1
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety — primary completion2009-07

Facts & assertions

4 sourced
Enrollment
376
Phase
PHASE3
Primary Completion Date
2009-07
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
Haloperidol
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Psychomotor Agitation
indication
Schizophrenia
indication